REFERENCES
- Lin WR, Lin HH, Lee SS, . Comparative study of the efficacy and safety of valacyclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect. 2001;34(2):138–142.
- Takayanagi A, Maehana T, Kyoda Y, Yanase M. Neurotoxicity of valacyclovir in a peritoneal dialysis patient. Hinyokika Kiyo. 2010;56(11):617–619.
- Okada T, Nakao T, Matsumoto H, . Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Clin Nephrol. 2002;58(2):168–170.
- Stathoulopoulou F, Dhillon S, Thodis H, Stathakis C, Vargemezis V. Evaluation of valacyclovir dosage reduction in continuous ambulatory peritoneal dialysis patients. Nephron. 2002;91(1):164–166.
- Izzedine H, Mercadal L, Aymard G, . Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. Am J Nephrol. 2001;21(2):162–164.
- Peyrière H, Branger B, Bengler C, . Neurologic toxicity caused by zelitrex (valacyclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement? Rev Med Interne. 2001;22(3):297–303.
- Kambhampati G, Pakkivenkata U, Kazory A. Valacyclovir neurotoxicity can be effectively managed by hemodialysis. Eur J Neurol. 2011;18(3):e33.
- Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS. Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am J Med. 1982;73(1A):202–204.